675 articles in this topic
A landmark ACSM consensus statement delivers the first evidence-based exercise guidelines for children and adolescents during and after cancer treatment.
PathPrism uses interpretable AI to find spatial biomarkers in colorectal cancer slides, predicting survival, mutations, and chemo benefit.
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
MD Anderson's Phase 1/2 trial explored injecting rituximab directly into spinal fluid to target CNS lymphoid malignancies.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
NCI-sponsored trial tests whether adding nivolumab to ipilimumab improves outcomes in stage III/IV unresectable melanoma.
A landmark Cell study reveals that the patient's own immune system—not just CAR T cells—decides outcomes in recurrent glioblastoma.
A comprehensive review reveals how combining genomics, proteomics, and metabolomics is uncovering new AML targets and improving patient outcomes.
A major review reveals how inflammaging and immunosenescence synergistically drive colorectal cancer in older adults, reshaping the tumor microenvironment.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
A Columbia University trial tested a digital care service to improve immunotherapy outcomes and reduce healthcare burden for minority lung cancer patients.
Peter Attia breaks down why standard screening guidelines fall short and how to build a personalized, risk-based breast cancer detection plan.
